Trial Profile
A multicenter, Randomized, Double-blind Study of tolerance, pharmacokinetics, and antiviral activity of Yimitasvir Phosphate capsule in Treatment-Nave Subjects with Chronic Genotype 1 HCV Infection
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Nov 2018
Price :
$35
*
At a glance
- Drugs Yimitasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 30 Oct 2016 Status changed from recruiting to completed, as reported by a TaiGen Biotechnology media release.
- 02 Nov 2015 New trial record